Authors
Loading...
This review highlights breakthroughs in DNA nanotechnology for tumor diagnosis and targeted drug delivery, emphasizing their biocompatibility and programmability.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: